Document AbbVie Inc. Guidance Including the Impact of Acquired IPR D and Milestones Expense (Unaudited) (in millions, except per share data) Quarter Ended
Saturday, September 30, 2023 1 min read
Key Takeaway: AbbVie Inc. has outlined its guidance for the third quarter of 2023, incorporating the impact of acquired IPR D and associated milestone expenses. The adjusted diluted earnings per share (EPS) guidance for Q3 is projected between $2.76 and $2.86, reflecting the impact of a $66 million expense. For the full year, the guidance adjusts EPS slightly to a range of $10.86 to $11.06. AbbVie states that any further expenses beyond Q3 cannot be reliably predicted at this time.
Market Sentiment Analysis
POSITIVE FACTORS
AbbVie has provided specific guidance on adjusted diluted EPS.
The company continues to monitor expenses related to acquisitions.
CONCERNS & RISKS
Q3 2023 incurred a milestone expense impacting EPS.
Acquired IPR D expenses are uncertain and affect future forecasts.
Full Press Release Details
Guidance Including the Impact of Acquired IPR D and Milestones Expense
(in millions, except per share data)
Quarter Ended September 30, 2023
Full-Year Ended December 31, 2023
Acquired IPR D and Milestones Expense
Adjusted Diluted EPS Range
Acquired IPR D and Milestones Expense
Adjusted Diluted EPS Range
Low
High
Low
High
Previously announced guidance excluding Q3 2023 acquired IPR D and milestones expense
$
-
$
2.80
$
2.90
$
430
$
10.90
$
11.10
Q3 2023 acquired IPR D and milestones expense
66
(0.04)
(0.04)
66
(0.04)
(0.04)
Guidance including Q3 2023 acquired IPR D and milestones expense a
$
66
$
2.76
$
2.86
$
496
$
10.86
$
11.06
a The Company's 2023 adjusted diluted EPS guidance excludes any impact from acquired IPR D and milestones expense that may be incurred beyond the third quarter of 2023, as both cannot be reliably forecasted.
Frequently Asked Questions
What was the acquired IPR D expense for Q3 2023?
The acquired IPR D expense for Q3 2023 was $66 million.
What is the adjusted diluted EPS range for full-year 2023?
The adjusted diluted EPS range for full-year 2023 is $10.90 to $11.10.
How does Q3 2023 impact the guidance?
Including Q3 2023, guidance shows adjusted diluted EPS of $2.76 to $2.86.
Is the guidance for acquired IPR D fully reliable?
No, the guidance excludes future impacts from acquired IPR D beyond Q3 2023.
What was the previously announced adjusted diluted EPS range?
The previously announced guidance was $2.80 to $2.90 for Q3 2023.